Taxotere Lawsuit Investigation
A Taxotere lawsuit is currently in the investigative phase.
Used to treat breast cancer, chemotherapy drug TAXOTERE™ is currently under investigation for a Taxotere lawsuit after a study found that 9.2% of women treated with this drug suffered permanent hair loss. While hair loss is a known side effect involved with chemotherapy treatments, hair typically grows back once treatment has subsided. With Taxotere™, however, in many women, the hair loss was permanent, and the drug manufacturers gave no warning of this serious risk.
It goes without saying that any diagnosis of cancer, followed by a treatment of chemotherapy, is difficult enough on its own. The physical impact and emotional toll can turn a patient’s life upside down. It is devastating to then finish the treatment and learn that the hair loss he or she suffered is permanent — especially when other equally effective treatments were available that would not have caused permanent hair loss.
Hair loss may include the hair on your head, underarm hair, pubic hair, eyebrows, and eyelashes.
While a Taxotere lawsuit is still in the initial phases of investigation, patients who underwent chemotherapy with Taxotere, suffered hair loss, and did not experience significant regrowth in 4-6 weeks after treatment, should consult a lawyer experienced with product liability matters to find out more about protecting their legal rights.
What is TAXOTERE?
Classified as a “plant alkaloid,” Taxotere™ (also known by its generic name, Docetaxel) belongs to the taxoid family and is extracted from the renewable needle biomass of yew plants. It is given intravenously (through the vein, and not in pill form), along with a 3-day premedication with a corticosteroid pill to reduce the severity of fluid retention and allergic reactions.
While it is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy, it has also been used to treat lung, prostate, stomach, and head and neck cancer.
In December 2015, The U.S. Food and Drug Administration amended its safety information about Taxotere to include a warning about alopecia, or permanent hair loss.
Additionally, the FDA issued a warning to Sanofi-Aventis for misleading doctors and patients with unsubstantiated superiority claims and by overstating the drug’s efficacy. A copy of the FDA’s warning letter can be found here.
Additional safety information about Taxotere can be found on this page of the FDA’s website.
Should I File a Taxotere Lawsuit?
The basis for a Taxotere Lawsuit
Currently in the case against Sanofi-Aventis for its failure to warn patients of the possibility of permanent hair loss from taking its drug, a Taxotere lawsuit is still in the investigative phase.
We are accepting intakes and conducting free and confidential Taxotere lawsuit evaluations for patients who have used Taxotere, experienced hair loss, and did not see hair regrowth within 4-6 weeks after completing the treatment. If you fit this criteria, we would be happy to speak with you directly and answer any questions you may have.
Lawyers from our firm have successfully represented numerous patients who suffered undisclosed side effects from using drugs such as Accutane, Actos, and Vioxx. We represent clients throughout the United States, and you can call us toll free at (866) 527-4278.